Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression

Hiroaki Saito, Yusuke Kono, Yuki Murakami, Yuji Shishido, Hirohiko Kuroda, Tomoyuki Matsunaga, Yoji Fukumoto, Tomohiro Osaki, Keigo Ashida, Yoshiyuki Fujiwara

研究成果: Article

13 引用 (Scopus)

抜粋

Background: A recent study demonstrated that immune-checkpoint molecules are associated with tumoral immune evasion. Materials and Methods: Programmed cell death protein 1 (PD-1) expression on CD4+ and CD8+ T-cells obtained from gastric cancer tissue was evaluated by multicolor flow cytometry. Immunohistochemical staining was also performed to evaluate programmed cell death ligand-1 (PD-L1) expression on gastric cancer cells. Results: There were statistically significant correlations between PD-L1 expression and age, histology, tumor size, depth of invasion, lymph node metastasis, lymphatic vessel invasion, venous invasion, and disease stage. The 5-year survival rates of patients with and without PD-L1-positive tumors were 48.9% and 80.7%, respectively, and the difference was statistically significant. Multivariate analysis indicated that PD-L1 expression was an independent prognostic indicator. The frequency of PD-1-positive CD4+ and CD8+ T-cells from gastric cancer tissue with PD-L1 expression was significantly more than that from gastric cancer tissue without PD-L1 expression. Conclusion: PD-L1 expression was related to a poor prognosis in patients with gastric cancer. Furthermore, PD-1 expression on T-cells was upregulated in patients with tumors with PD-L1 expression.

元の言語English
ページ(範囲)107-112
ページ数6
ジャーナルAnticancer research
38
発行部数1
DOI
出版物ステータスPublished - 01-2018
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Saito, H., Kono, Y., Murakami, Y., Shishido, Y., Kuroda, H., Matsunaga, T., Fukumoto, Y., Osaki, T., Ashida, K., & Fujiwara, Y. (2018). Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression. Anticancer research, 38(1), 107-112. https://doi.org/10.21873/anticanres.12197